Register today for our upcoming lunch seminar on Thursday, Feb. 29th at Catalyst Restaurant in Cambridge, MA from 11:30am to 1pm.
Leveraging Next-Generation Linker Technology to Achieve IND Submission
Progressing a new bioconjugate or antibody-drug conjugate (ADC) forward from discovery to IND can be a challenging and cumbersome process. The complexity of drug design, and considerable technical, safety, stability and scalability challenges, especially when it comes to the linker, make it incredibly difficult for developers to navigate the development pathway with speed and ease, while still ensuring an effective, high-quality product. Having a strong understanding of the varied and unique approaches that have been applied in effective linker design and available technologies can greatly impact the downstream success of your program.
Join Abzena’s SVP and Scientific Leader, Dr Petra Dieterich and Sr. Director of Bioconjugation Chemistry, Dr Nicolas Camper as they explore key considerations when designing and developing a bioconjugate or ADC and the impactful role that linker technologies play in accelerating and de-risking the development process to IND. Using case studies they will also provide insights into topics including oligonucleotide design and development, ADC to GMP requirements, and overall application of developability for ADC lead candidate selection.
What you’ll learn:
-How to maximize payload potential via site-specific conjugation
-How to achieve a more uniform DAR profile and stable attachment
-How to optimize your PK profile
-How Abzena’s unique ThioBridge conjugation technology improves stability, potency, and efficacy
Registration & Check-In: 11:30 am – 12 pm
Presentation & Q&A: 12:00 pm – 1 pm
*lunch will be included